摘要
目的:系统评价哌罗匹隆对比利培酮治疗精神分裂症的疗效与安全性,为临床提供循证参考。方法:计算机检索万方数据库、中文科技期刊数据库、中国期刊全文数据库、中国生物医学文献数据库和PubMed,收集哌罗匹隆(试验组)对比利培酮(对照组)治疗精神分裂症的临床随机对照试验(RCT),提取资料并按照改良后的Jadad评分标准评价纳入研究质量后,采用Rev Man5.0统计软件对各效应指标进行Meta分析。结果:共纳入12项RCT,合计1 050例患者。Meta分析结果显示,两组患者痊愈率比较,差异无统计学意义[OR=0.99,95%CI(0.75,1.30),P=0.93];对照组患者锥体外系反应发生率[OR=0.63,95%CI(0.43,0.92),P=0.02]、泌乳素水平升高发生率[OR=0.23,95%CI(0.14,0.38),P<0.001]和体质量增加发生率[OR=0.23,95%CI(0.13,0.39),P<0.001]显著高于试验组,差异均有统计学意义。结论:哌罗匹隆与利培酮治疗精神分裂症疗效相当,但哌罗匹隆的安全性优于利培酮。
OBJECTIVE： To systematically evaluate the therapeutic efficacy and safety of perospirone versus risperidone in the treatment of schizophrenia, and to provide evidence-based reference for clinical treatment. METHODS ： Retrieved from Wanfang da- tabase, VIP, CJFD, CBM and PubMed, randomized controlled trials （RCTs） of perospirone（trial group） vs. risperidone （control group） in the treatment of schizophrenia were collected. After data extraction and quality evaluation of included studies according to modified Jadad evaluation criteria, Meta-analysis of response indexes was performed by using Rev Man 5.0 statistical sottware. RE- SULTS： A total of 12 RCTs were included, involving 1 050 patients. Results of Meta-analysis showed, the cure rate of 2 groups had no statistical significance [OR=0.99,95%CI（075,1.30）,P=0.93]. The incidences of extrapyramidal reactions [OR=0.63,95% CI（0.43,0.92） ,P=0.02], the incidences of prolactin levels increasing [OR=0.23,95%CI（0.14,0.38）,P〈0.001] and the incidenc- es of weight gain [OR =0.23,95 % CI （0.13,0.39）, P〈 0.001] in control group were significantly higher than trial group, with statisti- cal significance （P〈0.05）. CONCLUSIONS： The therapeutic efficacy of perospirone and risperidone is similar in the treatment of schizophrenia, but the safety of perospirone is better than that of risperidone.
出处
《中国药房》
CAS
北大核心
2017年第24期3394-3396,共3页
China Pharmacy
基金
重庆市科技计划项目(No.cstc2015shmszx120073)
重庆市万州区科技计划项目(No.201403055)
关键词
哌罗匹隆
利培酮
精神分裂症
系统评价
疗效
安全性
Perospirone
Risperidone
Schizophrenia
Systematic review
Therapeutic efficacy
Safety
